<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05121519</url>
  </required_header>
  <id_info>
    <org_study_id>21-35115</org_study_id>
    <nct_id>NCT05121519</nct_id>
  </id_info>
  <brief_title>Does Eliminating Coffee Avoid Fibrillation?</brief_title>
  <acronym>DECAF</acronym>
  <official_title>A Pilot Randomized Controlled Trial to Assess Abstinence of Coffee Compared to Continued Consumption on Recurrent Atrial Fibrillation Following Electrical Cardioversion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Given both the increasing population impact of atrial fibrillation (AF) and the widespread&#xD;
      consumption of coffee in society, determining an associated benefit or risk of coffee&#xD;
      consumption on AF is of great clinical relevance. This pilot study will evaluate the effect&#xD;
      of randomly assigning participants undergoing electrical cardioversion to coffee abstinence&#xD;
      or coffee consumption over a 12 month period. This pilot study will provide the first,&#xD;
      randomized evaluation of coffee on AF outcomes and will provide important information on&#xD;
      whether or not coffee has any effect on AF recurrence.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to assess how abstinence of coffee compared to continued&#xD;
      consumption affects recurrent atrial fibrillation (AF) following electrical cardioversion. As&#xD;
      one of the most consumed beverages in the world, whether coffee has any effect on health&#xD;
      outcomes is of considerable interest to physicians, scientists, and individual consumers.&#xD;
      While significant data exist on the potential impact of coffee on many cardiometabolic&#xD;
      parameters, there is conflicting data on any role of coffee on AF.&#xD;
&#xD;
      Most studies so far have been observational in nature, limiting how much insight we have on&#xD;
      the role of coffee on AF. This study proposes to directly compare AF outcomes for patients&#xD;
      with AF that abstain from coffee verses those that continue coffee consumption.&#xD;
&#xD;
      A total of 200 AF patients undergoing electrical cardioversion will be enrolled in this study&#xD;
      (100 per arm), and followed for up to 12 months post cardioversion. Differences in AF&#xD;
      recurrence, symptoms, and development/recurrence of other arrhythmia will be compared between&#xD;
      the two groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 20, 2021</start_date>
  <completion_date type="Anticipated">October 20, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 20, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Recurrent AF</measure>
    <time_frame>12 months</time_frame>
    <description>We will compare the number of patient's with AF recurrence following direct current electrical cardioversion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of AF Recurrence</measure>
    <time_frame>12 months</time_frame>
    <description>We will compare time it takes for AF recurrence to occur following direct current electrical cardioversion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity in AF Symptoms</measure>
    <time_frame>12 months</time_frame>
    <description>We will compare any change in AF symptoms and severity (measured through survey questionnaires at 1, 3, 6, and 12 months) following direct current electrical cardioversion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity in Coffee Abstinence Symptoms</measure>
    <time_frame>12 months</time_frame>
    <description>We will compare any change in symptoms secondary to coffee abstention (measured through survey questionnaires at 1, 3, 6, and 12 month) following direct current electrical cardioversion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other arrhythmia onset or recurrence</measure>
    <time_frame>12 months</time_frame>
    <description>We will assess any change in rate of other arrhythmia occurrence determined through routine clinical care</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Coffee</condition>
  <arm_group>
    <arm_group_label>Avoid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will undergo this intervention for up to 12 months, or whenever their AF returns, whichever comes first.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Consume</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will undergo this intervention for up to 12 months, or whenever their AF returns, whichever comes first.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Consume coffee</intervention_name>
    <description>Drink coffee regularly (recommend at least 1 cup of coffee per day)</description>
    <arm_group_label>Consume</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Avoid coffee</intervention_name>
    <description>Abstain from coffee and other caffeinated beverages</description>
    <arm_group_label>Avoid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women â‰¥ 21 years of age&#xD;
&#xD;
          -  Sustained AF&#xD;
&#xD;
          -  Planned/scheduled direct current electrical cardioversion&#xD;
&#xD;
          -  Consumption greater than or equal to one cup of coffee per day sometime in the past 5&#xD;
             years&#xD;
&#xD;
          -  Willing and able to comply with coffee abstinence or continuation&#xD;
&#xD;
          -  Life expectancy of at least 1 year&#xD;
&#xD;
          -  Willing and able to return and comply with scheduled phone follow up visits&#xD;
&#xD;
          -  Willing and able to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Established allergy or adverse reaction to coffee&#xD;
&#xD;
          -  Stated inability to comply with coffee abstinence or continuation&#xD;
&#xD;
          -  AF ablation in preceding 6 months or planned in next 12 months&#xD;
&#xD;
          -  Recent cardiothoracic surgery in preceding 3 months&#xD;
&#xD;
          -  Cardioversion for atrial flutter rather than AF&#xD;
&#xD;
          -  Pregnancy or desire to get pregnant within next 6 months.&#xD;
&#xD;
          -  Current enrollment in an investigation or study of a cardiovascular device or&#xD;
             investigational drug that would interfere with this study&#xD;
&#xD;
          -  Any other criteria, which would make the patient unsuitable to participate in this&#xD;
             study as determined by the Principal Investigator (e.g., an uncontrolled drug and/or&#xD;
             alcohol addiction)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Greg Marcus, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chris Wong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Greg Marcus, MD</last_name>
    <phone>415-608-1565</phone>
    <email>greg.marcus@ucsf.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCSF Parnassus</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Greg Marcus, MD</last_name>
      <phone>415-608-1565</phone>
      <email>greg.marcus@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Greg Marcus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christopher Wong, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 26, 2021</study_first_submitted>
  <study_first_submitted_qc>November 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>coffee</keyword>
  <keyword>afib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 19, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/19/NCT05121519/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 19, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/19/NCT05121519/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

